PFIZER2023-04-012023-06-30 PFIZER2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member PFIZER2023-06-30 PFIZER2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2023-04-01 2024-03-31 2023-08-11 2023-08-04 INR Crores First quarter 14:00:00 16:15:00 2023-08-11 2023-08-11 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Standalone 5313600000.00 334600000.00 5648200000.00 861100000.00 1469000000.00 -171100000.00 935200000.00 28700000.00 155500000.00 1112300000.00 4390700000.00 1257500000.00 0.00 1257500000.00 334300000.00 -12100000.00 322200000.00 0.00 935300000.00 0.00 0.00 0.00 0.00 935300000.00 -8200000.00 927100000.00 0.00 0.00 457500000.00 10 20.44 20.44 0.00 0.00 20.44 20.44 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on August 11, 2023 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3.The financial results for the quarter ended June 30, 2023 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4.Figures for the quarter ended March 31, 2023 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2022 which were subject to a limited review by the statutory auditors. 5.During the quarter ended June 30, 2023 the Company had initiated a voluntary recall of Magnex, Magnamycin and Zosyn manufactured by Astral SteriTech Private Limited (“Astral”) and marketed / distributed by Pfizer Limited. While the issue is being investigated by Astral, based on their recommendation and out of an abundance of caution, the Company had a voluntarily recall from the market of all batches of these three products. The said products recorded a sale of Rs. 139.25 crore during the year ended March 31, 2023. 6.Net exceptional items aggregating Rs.33.00 crore for the year ended March 31, 2023 includes: a.Income of Rs.67.12 crore on account of sale of Business undertaking at Thane together with its related business assets and liabilities during the quarter ended March 31, 2023. b.Charge of Rs.86.71 crore on account of re-evaluation and reassessment of the risk relating to the Company’s old pending VAT / CST litigations, during the quarter ended March 31, 2023. c.Income of Rs.188.92 crore on account of transfer of certain primarily off patented and generic established medicines business (Upjohn Business) as a going concern together with its related business assets and liabilities during the quarter ended September 30, 2022. d.Charge of Rs.129.85 crore on account of Voluntary Retirement Scheme (VRS) and an additional charge of Rs. 6.48 crore (net) on account of restructuring to drive business transformation during the quarter ended June 30, 2022. 7.The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. Other Expenses 1112300000.00 Items that will not be reclassified subsequently to profit and loss -11000000.00 -11000000.00 -2800000.00